Skip to main content

Strong Sales Help Move Invitrogen Into the Black in Q2

SAN FRANCISCO, July 25 - Invitrogen yesterday reported an increase in second-quarter revenue and income as sales of its tool kits rose and R&D spending was trimmed back.


Revenue for the period ended June 30 rose to $164.3 million compared to $159.3 million one year ago.


Molecular-biology product lines with the strongest sales in the second quarter 2002 were cloning and gene expression, separations and analysis, and amplification products, which enjoyed 19 percent revenue growth year over year. However, the company's oligos and custom-services products fell 30 percent during in the same one-year period, Invitrogen said.


R&D spending in the current second quarter fell to $7.7 million from $9.8 million in the year-ago period.


Net income rose to $8.1 million, or $.15 per share, compared to a net loss of $35.1 million, or $.67 per share, for the second quarter 2001.


Invitrogen said it had $745 million in cash and cash equivalents as of June 30.


Click here for more information.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.